AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
AVEO’s strategy is to focus on development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies.
AVEO currently markets FOTIVDA® (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies.
Based on FOTIVDA’s demonstrated anti-tumor activity, tolerability profile and reduction of regulatory T-cell production, AVEO and its collaboration partners are continuing to develop tivozanib in immuno-oncology combinations in RCC and in additional cancer indications with significant unmet medical needs.
AVEO is also seeking to advance its pipeline of four wholly owned immunoglobulin G1 monoclonal antibody product candidates: ficlatuzumab, AV-380, AV-203 and AV-353.
AVEO continues to evaluate opportunities to collaborate with other pharmaceutical and biotechnology companies that share AVEO’s vision for oncology drug development, and seek partnerships that align with AVEO’s strategic, long-term corporate goals.